<bill session="106" type="h" number="4869" updated="2013-07-14T18:55:03-04:00">
  <state datetime="2000-07-18">REFERRED</state>
  <status>
    <introduced datetime="2000-07-18"/>
  </status>
  <introduced datetime="2000-07-18"/>
  <titles>
    <title as="introduced" type="short">Prescription Drug Fairness Act</title>
    <title as="introduced" type="official">To amend the Clayton Act to protect American consumers from foreign drug price discrimination.</title>
  </titles>
  <sponsor id="400575"/>
  <cosponsors/>
  <actions>
    <action state="REFERRED" datetime="2000-07-18">
      <text>Referred to the House Committee on the Judiciary.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSJU" name="House Judiciary" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Commerce"/>
    <term name="Drug industry"/>
    <term name="Foreign trade and international finance"/>
    <term name="Imports"/>
    <term name="Prescription pricing"/>
    <term name="Price discrimination"/>
    <term name="Wholesale trade"/>
  </subjects>
  <amendments/>
  <summary>7/18/2000--Introduced.
Prescription Drug Fairness Act - Amends the Clayton Act to deem: (1) the sale of a prescription drug by a manufacturer outside the United States to be the sale of such drug within the United States for purposes of provisions prohibiting price discrimination; and (2) discrimination in price between wholesalers within the United States and wholesalers outside the United States substantially to injure, destroy, or prevent competition with any person who either grants or knowingly receives the benefit of such discrimination, or with customers of either of them.</summary>
</bill>
